AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8712446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg)
Number of subjects: 30
Study 8712446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.50 mg/kg)
Number of subjects: 30
Study 8712446 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 2014460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.45 mg/kg
Number of subjects: 135
Study 2014460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.15 mg/kg
Number of subjects: 135
Study 2014460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg, droperidol 0.15 mg/kg (TMD)
Number of subjects: 135
Study 2014460 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 135
Study 7018788 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 96
Study 7018788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31478148 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA + hesperidin
Number of subjects: 2
Study 31478148 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA + placebo (Pc)
Number of subjects: 2
Study 30993350 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep extubation in the lateral position (group L)
Number of subjects: 92
Study 30993350 — intervention group
Group type: COMPARATOR
Intervention: Deep extubation in the supine position (group S)
Number of subjects: 92
Study 28750955 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterstrain
Number of subjects: 22
Study 28750955 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation
Number of subjects: 22
Study 25947235 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (group A)
Number of subjects: 39
Study 25947235 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine pleurodesis (group B)
Number of subjects: 39
Study 24062327 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily
Number of subjects: 1261
Study 24062327 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1261
Study 24062327 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1261
Study 20799264 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg every other week plus methotrexate
Number of subjects: 392
Study 20799264 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 392
Study 19740044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing half‐yearly monitoring of COPD patients with respiratory expert recommendations for the GP
Number of subjects: 200
Study 19740044 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 17045670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler of mitral annulus
Number of subjects: 36
Study 17045670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler of tricuspid annulus
Number of subjects: 36
Study 17045670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler derived left ventricular and right ventricular measurements
Number of subjects: 36
Study 17045670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid inflow E velocity and E(m) ratio
Number of subjects: 36
Study 15309011 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 888
Study 15309011 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors (Control)
Number of subjects: 888
Study 11730570 — intervention group
Group type: EXPERIMENTAL
Intervention: +Trans-T
Number of subjects: 12
Study 11730570 — intervention group
Group type: EXPERIMENTAL
Intervention: -Trans-T
Number of subjects: 12
Study 11730570 — intervention group
Group type: EXPERIMENTAL
Intervention: +M1
Number of subjects: 12
Study 11730570 — intervention group
Group type: EXPERIMENTAL
Intervention: -M1
Number of subjects: 12
Study 9491017 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child autotutorial group
Number of subjects: 0
Study 9491017 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling group
Number of subjects: 0
Study 9491017 — intervention group
Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 0
Study 7887119 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms.kg‐1 loading dose in 30 min, maintained with 1 microgram.kg‐1.h‐1 infusion)
Number of subjects: 20
Study 7887119 — intervention group
Group type: COMPARATOR
Intervention: Labetalol (0.2 mg.kg‐1 loading dose followed by 0.1 mg.kg‐1.h‐1 infusion)
Number of subjects: 20
Study 3369996 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary capsulotomy group
Number of subjects: 162
Study 3369996 — intervention group
Group type: COMPARATOR
Intervention: Capsule intact group
Number of subjects: 162
Study 3369996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (including nonrandomized cases)
Number of subjects: 162
Study 30339244 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduced individualized GH dose (GHRID; n = 27; 20 boys)
Number of subjects: 98
Study 30339244 — intervention group
Group type: COMPARATOR
Intervention: Unchanged individualized GH dose (GHUID; n = 38; 27 boys)
Number of subjects: 98
Study 30339244 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-based dose (GHFIX; n = 33; 25 boys)
Number of subjects: 98
Study 30339244 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRID group
Number of subjects: 98
Study 30339244 — intervention group
Group type: COMPARATOR
Intervention: GHUID group
Number of subjects: 98
Study 30339244 — intervention group
Group type: COMPARATOR
Intervention: GHFIX group
Number of subjects: 98
Study 28185715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 886
Study 28185715 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 886
Study 28185715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 886
Study 28185715 — intervention group
Group type: COMPARATOR
Intervention: Control (non-OAD)
Number of subjects: 886
Study 26192975 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (1 g/d)
Number of subjects: 109
Study 26192975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose at same dose)
Number of subjects: 109
Study 23223105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg
Number of subjects: 0
Study 23223105 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 45 mg
Number of subjects: 0
Study 22108476 — intervention group
Group type: EXPERIMENTAL
Intervention: Meriva (curcumin phytosome) at a dosage of 1 g/day (two tablets/day) for four weeks
Number of subjects: 25
Study 22108476 — intervention group
Group type: COMPARATOR
Intervention: Best possible management (control group)
Number of subjects: 25
Study 19619673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3 microg kg(‐1)min(‐1))
Number of subjects: 13
Study 19619673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16966348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Number of subjects: 174
Study 16966348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ganirelix acetate)
Number of subjects: 174
Study 15550800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care intervention for depression management over 24 months
Number of subjects: 326
Study 15550800 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 326
Study 11309016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intavent tube
Number of subjects: 54
Study 11309016 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt reinforced tube
Number of subjects: 54
Study 11309016 — intervention group
Group type: COMPARATOR
Intervention: Portex Blue Line tube
Number of subjects: 54
Study 9164316 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1265
Study 9164316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1265
Study 7696451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viscosity budesonide enema (2 mg/100 mL)
Number of subjects: 5
Study 7696451 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity budesonide enema (2 mg/100 mL)
Number of subjects: 5
Study 2821947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of enalapril (40 and, if necessary 60 mg once‐a‐day)
Number of subjects: 46
Study 2821947 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg and hydrochlorothiazide 25 and, if necessary, 50 mg once‐a‐day
Number of subjects: 46
Study 29325913 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIPP module (Computer‐Assisted Learning in Pediatrics Program)
Number of subjects: 789
Study 29325913 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-led case presentation feedback session
Number of subjects: 789
Study 29325913 — intervention group
Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 789
Study 26096889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 18.75 mg
Number of subjects: 42
Study 26096889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 37.5 mg
Number of subjects: 42
Study 26096889 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac potassium 50 mg
Number of subjects: 42
Study 26096889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24438902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy (6 doses intravenous over 14 weeks)
Number of subjects: 51
Study 24438902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy
Number of subjects: 51
Study 23519586 — intervention group
Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion (0.3‐3.0 nmol/min for local and 30‐300 nmol/min for systemic infusion)
Number of subjects: 60
Study 23519586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged systemic (Pyr(1))apelin‐13 infusion (30 nmol/min for 6 hours)
Number of subjects: 60
Study 23519586 — intervention group
Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion during sodium depletion and angiotensin II coinfusion
Number of subjects: 60
Study 20505173 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-artery stenting
Number of subjects: 2502
Study 20505173 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2502
Study 18782484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus protein-calorie supplementation (formula providing 250 kcal + 20 g protein)
Number of subjects: 48
Study 18782484 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 48
Study 16882533 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos exposure among those >or=65 years of age who had worked for the vermiculite mining company
Number of subjects: 7307
Study 16882533 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos exposure while in the military
Number of subjects: 7307
Study 16882533 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to vermiculite
Number of subjects: 7307
Study 16882533 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent contact with vermiculite through various exposure pathways
Number of subjects: 7307
Study 16882533 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing numbers of reported vermiculite exposure pathways
Number of subjects: 7307
Study 12927639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with pulsed ultrasound and interferential current (CTPI)
Number of subjects: 17
Study 12927639 — intervention group
Group type: COMPARATOR
Intervention: SHAM procedure
Number of subjects: 17
Study 11179104 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 68
Study 11179104 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 68
Study 9757976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodless cesarean section
Number of subjects: 108
Study 9757976 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaginal delivery or routine cesarean section)
Number of subjects: 108
Study 9757976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodless cesarean section (excluding zidovudine users)
Number of subjects: 108
Study 9757976 — intervention group
Group type: COMPARATOR
Intervention: Control group (excluding zidovudine users)
Number of subjects: 108
Study 8091436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards model
Number of subjects: 492
Study 8091436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards model applied to validation sample
Number of subjects: 492
Study 8091436 — intervention group
Group type: COMPARATOR
Intervention: Subtypes of stroke
Number of subjects: 492
Study 3395493 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session dietary change program
Number of subjects: 218
Study 3395493 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 218
Study 29438200 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 310
Study 29438200 — intervention group
Group type: COMPARATOR
Intervention: ABC/lamivudine (ABC/3TC)
Number of subjects: 310
Study 28019683 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg QD
Number of subjects: 224
Study 28019683 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg QW
Number of subjects: 224
Study 25231069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic scaler (AIR)
Number of subjects: 11
Study 25231069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (TIG)
Number of subjects: 11
Study 25231069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instruments (GRA)
Number of subjects: 11
Study 23066999 — intervention group
Group type: EXPERIMENTAL
Intervention: Print ad focused on depression
Number of subjects: 271
Study 23066999 — intervention group
Group type: COMPARATOR
Intervention: Nonrelevant comparison ad
Number of subjects: 271
Study 21429222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 18419399 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 0
Study 17168358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radical surgery plus pre- and intraoperative radiotherapy)
Number of subjects: 0
Study 17168358 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 14581425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with GM-CSF in adjuvant
Number of subjects: 26
Study 14581425 — intervention group
Group type: COMPARATOR
Intervention: Vaccination with dendritic cells (DCs)
Number of subjects: 26
Study 10881246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 30-46 mg/kg/day orally
Number of subjects: 267
Study 10881246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 10881246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 267
Study 8695025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 845XT automatic blood pressure monitor
Number of subjects: 417
Study 8695025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 8100 automatic blood pressure monitor
Number of subjects: 417
Study 8695025 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometers
Number of subjects: 417
Study 8695025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 845XT
Number of subjects: 417
Study 1565181 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxycholecalciferol (10 micrograms daily for 3 months)
Number of subjects: 12
Study 1565181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31858840 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy-ALA following fractional CO2 Laser
Number of subjects: 10
Study 31808404 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-shift operation mode
Number of subjects: 92
Study 31808404 — intervention group
Group type: COMPARATOR
Intervention: Single player mode
Number of subjects: 92
Study 30485924 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS) administered daily for 1 month
Number of subjects: 283
Study 30485924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skimmed milk without probiotic) administered daily for 1 month
Number of subjects: 283
Study 30485924 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS)
Number of subjects: 283
Study 30485924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skimmed milk without probiotic)
Number of subjects: 283
Study 26407124 — intervention group
Group type: EXPERIMENTAL
Intervention: pirfenidone tablets (0.4 g) with food
Number of subjects: 12
Study 26407124 — intervention group
Group type: EXPERIMENTAL
Intervention: pirfenidone tablets (0.4 g) with grapefruit juice
Number of subjects: 12
Study 26407124 — intervention group
Group type: COMPARATOR
Intervention: fasted group (control)
Number of subjects: 12
Study 23352729 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot and hand massage
Number of subjects: 80
Study 22641248 — intervention group
Group type: EXPERIMENTAL
Intervention: VASS prosthesis
Number of subjects: 20
Study 22641248 — intervention group
Group type: COMPARATOR
Intervention: Standard suction socket system prosthesis
Number of subjects: 20
Study 22529513 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week interval training program (60-79% HR max reserve) for 45-60 minutes
Number of subjects: 245
Study 22529513 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 245
Study 17697908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg under fed conditions
Number of subjects: 24
Study 17697908 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine 20 mg under fasting conditions
Number of subjects: 24
Study 17697908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg under both conditions
Number of subjects: 24
Study 16120152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Sea salt balneophototherapy
Number of subjects: 60
Study 16120152 — intervention group
Group type: COMPARATOR
Intervention: Narrowband ultraviolet B monotherapy
Number of subjects: 60
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma fatty acids
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased lipoprotein (a)
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased acyl carnitine levels
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary total and free acyl carnitine excretion
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased plasma free carnitine levels
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with duration of DM or HbA1c
Number of subjects: 0
Study 12099395 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for plasma free carnitine determinations
Number of subjects: 0
Study 10655708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in breast conservation therapy (BCT)
Number of subjects: 0
Study 10655708 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost irradiation to the tumor bed
Number of subjects: 0
Study 10655708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation to lymph node areas
Number of subjects: 0
Study 7755528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 52
Study 7755528 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 52
Study 2305019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Number of subjects: 0
Study 2305019 — intervention group
Group type: COMPARATOR
Intervention: Topical salicylic acid
Number of subjects: 0
Study 2305019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2305019 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study 7288894 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin E per day for 9 or more weeks
Number of subjects: 0
Study 7288894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin E per day for 9 or more weeks
Number of subjects: 0
Study 7288894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31843964 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS infusion
Number of subjects: 10
Study 31843964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29667541 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic absorbable monofilament sutures
Number of subjects: 107
Study 29667541 — intervention group
Group type: COMPARATOR
Intervention: Synthetic absorbable multifilament sutures
Number of subjects: 107
Study 28419192 — intervention group
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine 1 mg TID
Number of subjects: 0
Study 28419192 — intervention group
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine 2 mg TID
Number of subjects: 0
Study 28419192 — intervention group
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine 4 mg TID
Number of subjects: 0
Study 28419192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28419192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (4 mg TID)
Number of subjects: 0
Study 28419192 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug groups
Number of subjects: 0
Study 26577263 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA-guided treatment strategy
Number of subjects: 598
Study 26577263 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 598
Study 23841565 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane (right eye) and Eyestil (left eye)
Number of subjects: 43
Study 23841565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tears Naturale II (right eye) and Refresh Tears (left eye)
Number of subjects: 43
Study 23841565 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyestil
Number of subjects: 43